Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in:

Open Access 01-12-2024 | Research

CRHBP, a novel multiple cancer biomarker connected with better prognosis and anti-tumorigenicity

Authors: Wonbeak Yoo, Hyunji Choi, Jieun Lee, Yeeun Lee, Kyung Chan Park, Kyunghee Noh

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Background

The corticotropin-releasing hormone-binding protein (CRHBP) plays a crucial role in regulating corticotropin release. Little is known about the role of CRHBP, a major regulator of neuroendocrine, autonomic, and stress adaptation, in tumors. In this study, we aimed to investigate the clinical and molecular landscapes of CRHBP in various types of tumors.

Methods

We investigated the role of CRHBP in different types of tumors using publicly available databases and performed a comparative expression analysis of CRHBP-related genes in pan-cancer prognosis using methylation profiling, tumor-infiltrating immune cell expression analysis, gene enrichment analysis, and protein-protein interaction analysis, identified common pathways, and in vitro evaluation.

Results

We evaluated CRHBP expression across tumor and corresponding normal tissues using the data from The Cancer Genome Atlas and the Genotype-Tissue Expression database. CRHBP was downregulated in most tumors and was identified as an important factor for predicting the prognosis of patients with cancer. Intracellular metabolic pathways and hormone-related processes were involved in the functional mechanisms of CRHBP. Mechanistically, the downregulation of CRHBP was attributed to the upregulation of four miRNAs in most tumors, and CRHBP expression was related to tumor-infiltrating immune cells in tumors. Overexpression of CRHBP significantly inhibited cell proliferation of LUAD, LIHC, and KIRC cell lines, while inhibition of cell mobility was found only in KIRC and HCC cells.

Conclusions

This study provides a comprehensive summary of the systemic role of CRHBP expression in various types of tumors, highlighting the prognostic importance and clinical significance of tumors. Furthermore, CRHBP decreases cell proliferation and mobility in cancer cell lines associated with OS and DFS, further research is needed to understand the underlying mechanisms and explore clinical applications.
Appendix
Available only for authorised users
Literature
1.
Westphal NJ, Seasholtz AF. CRH-BP: the regulation and function of a phylogenetically conserved binding protein. Front Biosci. 2006;11:1878–91.PubMedCrossRef
2.
Ketchesin KD, Stinnett GS, Seasholtz AF. Corticotropin-releasing hormone-binding protein and stress: from invertebrates to humans. Stress. 2017;20(5):449–64.PubMedPubMedCentralCrossRef
3.
Novoselova TV, King PJ, Guasti L, Metherell LA, Clark AJL, Chan LF. ACTH signalling and adrenal development: lessons from mouse models. Endocr Connect. 2019;8(7):R122–30.PubMedPubMedCentralCrossRef
4.
Gallo-Payet N. 60 YEARS OF POMC: adrenal and extra-adrenal functions of ACTH. J Mol Endocrinol. 2016;56(4):T135–156.PubMedCrossRef
5.
Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol. 1994;15(4):321–50.PubMedCrossRef
6.
Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress. 2004;7(2):75–83.PubMedCrossRef
7.
Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53(4):865–71.PubMedCrossRef
8.
Borowski KS, Clark EA, Lai Y, Wapner RJ, Sorokin Y, Peaceman AM, Iams JD, Leveno KJ, Harper M, Caritis SN, et al. Neonatal genetic variation in Steroid Metabolism and Key Respiratory function genes and perinatal outcomes in single and multiple courses of corticosteroids. Am J Perinatol. 2015;32(12):1126–32.PubMedPubMedCentralCrossRef
9.
Kolasa M, Faron-Gorecka A, Kusmider M, Szafran-Pilch K, Solich J, Zurawek D, Gruca P, Papp M, Dziedzicka-Wasylewska M. Differential stress response in rats subjected to chronic mild stress is accompanied by changes in CRH-family gene expression at the pituitary level. Peptides. 2014;61:98–106.PubMedCrossRef
10.
Xia HB, Wang HJ, Fu LQ, Wang SB, Li L, Ru GQ, He XL, Tong XM, Mou XZ, Huang DS. Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2018;16(3):3681–9.PubMedPubMedCentral
11.
Wang Z, Li M, Liu Y, Qiao Z, Yang L, Liu B, Bai T. CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex. Cancer Gene Ther. 2022;29(8–9):1217–27.PubMedCrossRef
12.
Tezval H, Atschekzei F, Peters I, Waalkes S, Hennenlotter J, Stenzl A, Becker JU, Merseburger AS, Kuczyk MA, Serth J. Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer. BMC Cancer. 2013;13:199.PubMedPubMedCentralCrossRef
13.
Spieker J, Ackermann A, Salfelder A, Vogel-Hopker A, Layer PG. Acetylcholinesterase regulates skeletal in Ovo Development of Chicken limbs by ACh-Dependent and -independent mechanisms. PLoS ONE. 2016;11(8):e0161675.PubMedPubMedCentralCrossRef
14.
Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286–287:18–24.PubMedCrossRef
15.
Liu H, Tang T. Pan-cancer genetic analysis of disulfidptosis-related gene set. Cancer Genet. 2023;278–279:91–103.PubMedCrossRef
16.
Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: identification of potential biomarkers, drug targets and drug-target interactions. Drug Resist Updat. 2020;48:100662.PubMedCrossRef
17.
18.
19.
Liu YG, Jiang ST, Zhang L, Zheng H, Zhang T, Zhang JW, Zhao HT, Sang XT, Xu YY, Lu X. Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study. Eur J Med Res. 2023;28(1):229.PubMedPubMedCentralCrossRef
20.
Van Den Eede F, Van Broeckhoven C, Claes SJ. Corticotropin-releasing factor-binding protein, stress and major depression. Ageing Res Rev. 2005;4(2):213–39.PubMedCrossRef
21.
Petraglia F, Florio P, Simoncini T, Woods RJ, Giuntini A, Gremigni R, Serra GB, Genazzani AR, Lowry PJ. Cord plasma corticotropin-releasing factor-binding protein (CRF-BP) in term and preterm labour. Placenta. 1997;18(2–3):115–9.PubMedCrossRef
22.
Ketchesin KD, Stinnett GS, Seasholtz AF. Binge drinking decreases corticotropin-releasing factor-binding protein expression in the Medial Prefrontal cortex of mice. Alcohol Clin Exp Res. 2016;40(8):1641–50.PubMedPubMedCentralCrossRef
23.
Tezval H, Dubrowinskaja N, Peters I, Reese C, Serth K, Atschekzei F, Hennenlotter J, Stenzl A, Kuczyk MA, Serth J. Tumor specific epigenetic silencing of Corticotropin releasing hormone -binding protein in renal cell Carcinoma: Association of Hypermethylation and Metastasis. PLoS ONE. 2016;11(10):e0163873.PubMedPubMedCentralCrossRef
24.
Zhou G, Li S, Xia J. Network-based approaches for multi-omics integration. Methods Mol Biol. 2020;2104:469–87.PubMedCrossRef
25.
Pirih N, Kunej T. Toward a taxonomy for Multi-omics Science? Terminology Development for Whole Genome Study approaches by Omics Technology and Hierarchy. OMICS. 2017;21(1):1–16.PubMedCrossRef
26.
Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andre F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617–35.PubMedPubMedCentralCrossRef
27.
Pal M, Muinao T, Boruah HPD, Mahindroo N. Current advances in prognostic and diagnostic biomarkers for solid cancers: detection techniques and future challenges. Biomed Pharmacother. 2022;146:112488.PubMedCrossRef
28.
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, Tian X, Guan X, Cen X, Zhao Y. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):132.PubMedPubMedCentralCrossRef
29.
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808–25.PubMedPubMedCentralCrossRef
30.
Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.CrossRef
31.
Li Y, Wang X, Hou X, Ma X. Could inhibiting the DNA damage repair checkpoint rescue Immune-checkpoint-inhibitor-resistant endometrial Cancer? J Clin Med 2023, 12(8).
32.
Drake TM, Soreide K. Cancer epigenetics in solid organ tumours: a primer for surgical oncologists. Eur J Surg Oncol. 2019;45(5):736–46.PubMedCrossRef
33.
Casalino L, Verde P. Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. Genes (Basel) 2020, 11(8).
34.
35.
Maruyama R, Choudhury S, Kowalczyk A, Bessarabova M, Beresford-Smith B, Conway T, Kaspi A, Wu Z, Nikolskaya T, Merino VF, et al. Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet. 2011;7(4):e1001369.PubMedPubMedCentralCrossRef
36.
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115.PubMedCrossRef
37.
Kwa MQ, Herum KM, Brakebusch C. Cancer-associated fibroblasts: how do they contribute to metastasis? Clin Exp Metastasis. 2019;36(2):71–86.PubMed
38.
Iwahori K. Cytotoxic CD8(+) lymphocytes in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1224:53–62.PubMedCrossRef
39.
40.
Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the Tumor Microenvironment. Trends Immunol. 2016;37(3):208–20.PubMedPubMedCentralCrossRef
41.
Khadka S, Druffner SR, Duncan BC, Busada JT. Glucocorticoid regulation of cancer development and progression. Front Endocrinol (Lausanne). 2023;14:1161768.PubMedCrossRef
42.
Sato N, Motoi F, Tajiki H, Kawaguchi K, Ohtsuka H, Takadate T, Nakagawa K, Takagi K, Suzuki T, Katayose Y, et al. Expression of corticotropin-releasing hormone and its receptors may be Associated with Survival Rate in Pancreatic Cancer. Gastro Hep Adv. 2023;2(1):147–55.PubMedCrossRef
43.
44.
Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–9.PubMedPubMedCentralCrossRef
45.
Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27.PubMedPubMedCentralCrossRef
46.
Li Y, Ge D, Lu C. The SMART app: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenetics Chromatin. 2019;12(1):71.PubMedPubMedCentralCrossRef
47.
Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–31.PubMedCrossRef
48.
McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, Bartel DP. The biochemical basis of microRNA targeting efficacy. Science 2019, 366(6472).
49.
50.
Xu F, Wang Y, Ling Y, Zhou C, Wang H, Teschendorff AE, Zhao Y, Zhao H, He Y, Zhang G, et al. dbDEMC 3.0: Functional Exploration of differentially expressed miRNAs in cancers of human and model organisms. Genomics Proteom Bioinf. 2022;20(3):446–54.CrossRef
51.
Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–97.PubMedCrossRef
52.
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14.PubMedPubMedCentralCrossRef
53.
Rodchenkov I, Babur O, Luna A, Aksoy BA, Wong JV, Fong D, Franz M, Siper MC, Cheung M, Wrana M, et al. Pathway Commons 2019 Update: integration, analysis and exploration of pathway data. Nucleic Acids Res. 2020;48(D1):D489–97.PubMed
54.
Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, Lachmann A, Wojciechowicz ML, Kropiwnicki E, Jagodnik KM, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1(3):e90.PubMedPubMedCentralCrossRef
55.
Yoo W, Kim AK, Kook HU, Noh K. Comprehensive analysis on clinical significance and therapeutic targets of LDL receptor related protein 11 (LRP11) in liver hepatocellular carcinoma. Front Pharmacol. 2024;15:1338929.PubMedPubMedCentralCrossRef
56.
Metadata
Title
CRHBP, a novel multiple cancer biomarker connected with better prognosis and anti-tumorigenicity
Authors
Wonbeak Yoo
Hyunji Choi
Jieun Lee
Yeeun Lee
Kyung Chan Park
Kyunghee Noh
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03562-4

Other articles of this Issue 1/2024

Exploring the clinical implications and applications of exosomal miRNAs in gliomas: a comprehensive study

Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

Smad2/3/4 complex could undergo liquid liquid phase separation and induce apoptosis through TAT in hepatocellular carcinoma

Therapeutic combinations of exosomes alongside cancer stem cells (CSCs) and of CSC-derived exosomes (CSCEXs) in cancer therapy

Acid affairs in anti-tumour immunity

Assessing the impact of extracellular matrix fiber orientation on breast cancer cellular metabolism

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits